RTOG-1205
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone As Treatment for Recurrent Glioblastoma
Principal Investigator
Status
Terminated
Open to Accrual
December 20, 2012
Closed to Accrual
April 28, 2016
Closed to Accrual & Treatment
November 25, 2020
Terminated
December 22, 2022
Disease Site
Brain [BN] Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To establish an improvement in overall survival in recurrent GBM patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.
Patient Population
Patients with recurrent glioblastoma or variant (gliosarcoma or giant cell glioblastoma etc).
Target Accrual
178
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
